FARMINGDALE, N.Y., March 16, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, laparoscopic surgery and other surgical applications, has donated a Bone Scalpel® unit to Spine Overseas for mission work at the Karl Heusner Memorial Hospital in Belize.
"We are thankful for the donation made by Misonix, allowing us to better treat individuals in need to allow them to return to a healthy and productive life. I am a big fan of the Bone Scalpel from Misonix, and promote its use everywhere I go. I feel it is among the top 2-3 innovations introduced into spine surgery over the past decade," said Peter Gabos, M.D., from Alfred I. DuPont Hospital for Children in Wilmington, DE.
"The relationship with the Belize mission is an on-going commitment, and one that I anticipate will be highly visible," notes Dr. Gabos. "The Karl Heusner Memorial Hospital is fast becoming a center of excellence in spine surgery, and there is a huge training and education component for many South American spinal surgeons."
Founded by orthopaedic spine surgeons Dr. John Williams and Dr. Jim Youssef, Spine Overseas (www.spineoverseas.org) is now supported by a volunteer team of 16 professionals from the United States and Canada. By partnering with local healthcare providers in developing countries, as well as innovative device companies, Spine Overseas is dedicated to improving patient care and surgical education globally. In 2012, the Spine Overseas team, in partnership with Karl Heusner Memorial Hospital, performed the very first scoliosis surgery in the history of Belize.
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, "We are thankful to the dedicated surgeons committed to helping those in need on this mission to Belize and their ongoing commitment to improving patients' lives. With the Bone Scalpel these surgeons have been able to perform spine surgery that is safer and more efficient. We want to thank Dr. Gabos, the mission's many spine surgeons, and the medical staff for their charitable work in Belize. Their efforts to help the less fortunate are inspirational."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.